Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3031379 | 0.98 | OPRM1 (0.56) | OPRM1SIGMAR1NPY5RADRA1AKCNH2 | |
| SCHEMBL3225883 | 0.91 | OPRM1 (0.52) | OPRM1SIGMAR1NPY5RADRA1AKCNH2 | |
| SCHEMBL669637 | 0.85 | OPRM1 (0.43) | OPRM1SIGMAR1NPY5RADRA1AKCNH2 | |
| SCHEMBL738186 | 0.85 | NPY5R (0.44) | OPRM1SIGMAR1NPY5RADRA1AKCNH2 | |
| SCHEMBL736968 | 0.85 | NPY5R (0.49) | OPRM1SIGMAR1NPY5RADRA1AKCNH2 | |
| SCHEMBL23459280 | 0.85 | OPRM1 (0.43) | OPRM1SIGMAR1NPY5RADRA1AKCNH2 | |
| SCHEMBL737144 | 0.85 | OPRM1 (0.43) | OPRM1SIGMAR1NPY5RADRA1AKCNH2 | |
| SCHEMBL11372471 | 0.85 | HSD11B1 (0.45) | OPRM1SIGMAR1NPY5RADRA1AKCNH2 | |
| SCHEMBL670724 | 0.84 | SSTR5 (0.53) | SSTR5 | |
| SCHEMBL3219771 | 0.84 | OPRM1 (0.53) | OPRM1SIGMAR1NPY5RADRA1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742110-B2 | Spiroxazolidinone compounds | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8575167-B2 | Spiro compounds having stearoyl-CoA desaturase action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20130131042-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20100197699-A1 | I-OXA-3-Azaspiro (4.5) Decan-2-One And 1-OXA-3, 8-Diazaspiro (4.5) Decan-2-One Derivatives For The Treatment of Eating Disorders | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2121673-A1 | I-OXA-3-AZASPIRO (4.5) DECAN-2-ONE AND 1-OXA-3, 8-DIAZASPIRO (4.5) DECAN-2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | Glaxo Group Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| WO-2008092887-A1 | I-OXA-3-AZASPIRO (4.5) DECAN-2-ONE AND 1-OXA-3, 8-DIAZASPIRO (4.5) DECAN-2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20060052597-A1 | Aryloxyalkylamine derivatives as h3 receptor ligands | BEST DESMOND J | 2006-03-09 | — | — | US | disclosed |
| EP-1554260-A1 | ARYLOXYALKYLAMINE DERIVATIVES AS H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004037800-A1 | ARYLOXYALKYLAMINE DERIVATES AS H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
| US-4255432-A | ANTIHYPERTENSIVE AGENTS, ANTIHISTAMINES, BRONCHODILATOR AGENTS, ANTIVASOSPASTIC AGENTS | SYNTEX (U.S.A.) INC. (US) | 1981-03-10 | — | — | US | disclosed |
| US-4244961-A | 1-Oxa-3,8-diazaspiro[4.5]decan-2-ones antihypertensive agents | SYNTEX (U.S.A.) INC. (US) | 1981-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052597-A1 | Aryloxyalkylamine derivatives as h3 receptor ligands | HRH3, HTR6, HTR4 | OPRM1 32/4885SIGMAR1 86/4885NPY5R 320/4885 |
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | OPRM1 15/4885SIGMAR1 11/4885NPY5R 385/4885 |
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | SCD, SPR, SCD5 | OPRM1 2864/4885SIGMAR1 1459/4885NPY5R 2775/4885 |
| US-20100197699-A1 | I-OXA-3-Azaspiro (4.5) Decan-2-One And 1-OXA-3, 8-Diazaspiro (4.5) Decan-2-One Derivatives For The Treatment of Eating Disorders | NPY5R, NPY1R, NPY4R | OPRM1 63/4885SIGMAR1 52/4885NPY5R 1/4885 |
| US-20130131042-A1 | SPIROXAZOLIDINONE COMPOUNDS | SSTR5, SSTR2, SSTR4 | OPRM1 1086/4885SIGMAR1 483/4885NPY5R 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.